Q1 2022 Results
Company overview
CRM
Financial performance
Immunology
BeovuⓇ
-
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
VEGF Inhibitor
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04278417 (CRTH258D2301)
Diabetic retinopathy
Phase 3
706
Change from Baseline in BCVA
Arm1: RTH258 (brolucizumab) 6 mg/50uL
Arm2: Panretinal photocoagulation laser initial treatment followed with additional
PRP treatment as needed
Patients with proliferative diabetic retinopathy
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
82 Investor Relations | Q1 2022 Results
References
Abbreviations
Hematology
Biosimilars
Global Health
NOVARTIS | Reimagining MedicineView entire presentation